StageZero Life Sciences Ltd.

Good morning, ladies and gentlemen, and welcome to the Stage Zero Life Sciences First Quarter Financials Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions after the presentation. If you would like to enter the queue at any time, you may press star 1 on your telephone keypad. If you wish to remove yourself from queue, you may press star 2. It is now my pleasure to turn the floor over to your host, Rebecca Greco, Head of Investor Relations. Rebecca, the floor is yours.

Thank you, Tom. Good morning, everyone, and thank you for joining the Stage Zero Life Sciences first quarter 2022 earnings conference call. Joining me today is Stage Zero Chairman and CEO, James Howard Tripp, and CFO and COO, Matthew Pietras. Please note that management's discussion today will contain forward-looking statements about anticipated results and future prospects. Forward-looking statements involve a number of risks and uncertainties, and Stage 0's results may differ materially from those discussed today. Investors should consult the company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The company disclaims any obligation to update these forward-looking statements, except as required by law. On today's call, Madge will refer to non-GAAP-adjusted EBITDA. This metric excludes certain items discussed in our press release under the heading Discussion of Non-GAAP Financial Measures, and any other items that management believes should be excluded when reviewing continuing operations. The reconciliations of Stage Zero's non-GAAP measures to the comparable GAAP measures are available in the financial tables of the Q4 2021 financial results press release on Stage Zero's website. With that, I would like to turn the call over to James Howard-Tripp, Stage Zero's Chief Executive Officer. James, please go ahead.

James Howard-Tripp, Chief Executive Officer, Stage Zero Good. Thank you, Rebecca, and good morning, everyone. Thank you very much for joining us. I was going to say it's been a busy quarter. In fact, it's been a very busy two years. I'm going to start with 2021 and just a recap of, I think, what we were building as we take it through, because I think it spills over very nicely into the quarter and then sort of where we are now. So if you look at what we did in 2021, clearly time of COVID, we used the COVID testing to dramatically expand our capabilities. I think equally as important with this is we brought in a whole series of very large partners, which meant that not only did we get the organization used to working with very large partners, but we got them used to working at a very, very fast pace in terms of all of this. We, instead of partnering with Care Oncology, and as groups we talked about that, we actually decided there was much better energy by bolting the two organizations together. And so we moved to actually acquired care oncology, which we did in September of last year, and obviously pulling all of those pieces together has been absolutely critical. We launched Aristotle in the U.S. and the greater Toronto area, and I'm gonna come back to that in just a moment. We launched the AVERT program in the U.S. AVERT, in actual fact, will go even a little earlier than Aristotle in terms of providing highlights as to where you could look should you be developing cancer. It ties very importantly to what Aristotle does because obviously if you find something on avert, you're going to then want to have a look in Aristotle. It ties to a series of strategies we're talking to healthcare groups about as well. We established the On-Site Clinic in Richmond, Virginia. This was to begin to build out physical presence from a clinic perspective something that we've now duplicated in a relatively large number of cities across the U.S. We broadened our strategic relationships. We talked about this just a little earlier. But if you look at the likes of the people we were able to bring to the table, Rexall, Sobeys, that's just on the Canadian side. You go to larger groups like government in dealing with it. You go to Maricopa County. You go to testing the U.S. State Department. Obviously, there's an interest for us beyond COVID, and this is what we're working with now. We commenced trading on OTCQB. That was important because it's part of our strategy of trying to get traded properly in the U.S. So being able to provide that kind of access is important, and it is still an intention that sometime in the future when appropriate to look at a senior board listing in the U.S. We expanded the management team of the board. Absolutely critical. If you look at who we have around the management table now, particularly building out even to our strategic advisory boards, we've got an absolutely superb group of people. Been there before, done it before, know how to do this, all of that really important. We raise money. Absolutely and critical. I think when I go to, when Matt first joined us, and I've mentioned this before, Matt's comment was good grief. You haven't really done all of this on 25 million in the last five years, but that's exactly what we had done. And I'd ask you to reflect on that on literally how much we achieve with literally how little money is we made it through, but we've built it and we've grown it. In addition to that, we did reasonable revenue last year. 5 million is obviously we would expect to surpass that this year. but 5 million is a good start. It was mostly COVID, but towards the latter part of the year, we started to transition into the cancer revenue. We've continued that through. That is really important. And I think the final piece with this, the revenue is 1.5 million in the fourth quarter. I think that's important because it was a mix of COVID and, sorry, it was a mix of COVID and cancer. If we move forward to what we've done in the first quarter, we continue that pace. We haven't slowed down in any way. If anything, we've actually picked up the pace. We've fully completed the integration of care oncology into and we've started scaling the various programs, but all over the world, US, Canada, UK, and Europe. That's absolutely critical. You've got to acquire an organization. You've got to bring it inside. You've got to get everything straightened out so that the systems work. Everything needs to be regulatory compliant, all of the boring things that go on in the background. But they have to be there before you can actually begin to fully scale. With those in place, we've started to scale. We're also getting to know where to push. And I think we're seeing some of that. People are obviously excited by what we've done with COC+. That's a result of knowing exactly where to push and how to push and beginning that process. We launched Divert in the U.S., critical. We extended the capability of the COC protocol to Europe, critical. Europe has 780 million people. Being able to access that, having the infrastructure to do that, knowing where to begin first, second, and third, absolutely critical. But all of that to build out. It's a market that is twice the size of the U.S. We extended the availability in the U.K. by launching VIRT into the U.K. as well. We started to participate in key summits. If you look at the Sea Summit, we were one of the key groups together with Jamie and Simon as they put that together to decide that we needed to take the entire concept of liquid biopsy and the fact that people can access, it's developing, it's true, it's real, it works, there's good solid science behind it. And so we help take it out. As you see, who was actually at the table as well, positions us very nicely as one of the leaders in the field, and that has led to a whole series of additional speaking engagements, particularly with large organizations to take it out. You can follow some of this if you look at our social media. We expanded the marketing programs for Aristotle into multiple new cities in the U.S. And this is important because speaking with some of our Canadian shareholders, I think there's a belief that Aristotle has been taken only to the GTA and that it's essentially not available anywhere else. It is available in the U.S. It's in multiple cities. Pretty much what we've done in the GTA and what we've done in Richmond is what we're doing literally city group by city group as we take it out. And so literally, month after month, we're actually adding to these and building it all out. I'll talk to the interaction between the various programs in a moment as well, because the COC protocol, Aristotle, AVERT, COC+, all tie and all address the same groups of people. We closed the additional financing last quarter and our revenue of 1.3 million. If you look at the fact that we were moving from COVID, COVID revenue in fact has come down very markedly. It's been picked up by the cancer revenue. It's beginning to move in the right direction. And so we now intend to continue to build on that. So where are we going from here? I think what people want to see is, you know, what do we have in line for 2022? What is it that we expect to do this year? And I'll walk through this with a little bit of detail. The first thing that we've done as we've talked to is we've been able to demonstrate that the promotion is dollar sensitive. So in other words, having got the various programs in place, if we push on it in the right way, we can actually get the incremental growth out of it. That is absolutely critical. So as we now begin to push all of those pieces in place, and again, I will reference COC Plus, which I think people saw this weekend. That's exactly what you do. That's the push as we drive on forward. We're expanding access to Aristotle in Canada. We'll go live in Alberta, the Calgary area in the next little while. We're also bringing up Quebec as we drive through. Those are the first, or I should say the first of the three jurisdictions, GTA being the other that we will drive through and we will then decide where we go from there. We're expanding large access across the US as I was talking about, but we're in the process right now of bringing up all of these additional states. In fact, right now we're live in Texas, we're live in Pennsylvania, we're live in Connecticut. We're about to go live in New Jersey. We're live in North Carolina. All of these are there. The additional states will come on as we move on out. The obvious intent is we want to make sure that we're very widely distributed. Why not just throw it out to everyone out there? We could do. But if you think about the fact that we're still coming out of COVID, you think about the support systems that have to be in place. You think about how we have to deal with the patients. It's absolutely critical. And I'll talk to this a little bit more when I actually go into the various programs. It has to be in a very staged way so that we can scale appropriately. We're back partnering with some innovative clinical groups. This is where we have typically been as these groups begin to come back on stream, get back to normal business. They're obviously open to this again. This includes the employer base. And there will be more to hear about this as we move out over the next few months. We want to launch Avert in the European Union. I think as I mentioned earlier, you know, 750, 780 million people, depending upon how you look at it, an extremely large market. Avert is often the leading edge for a lot of the pieces where people start. And so I'll take you to a discussion that we're having with some of the larger healthcare groups at the moment. They may do internal screens that essentially just say cancer, no cancer. What they're looking for is a way to actually then definitively be able to sort out what kind of cancer those patients might have and in actual fact to give it much, much greater certainty around probability. That's where they move to us. And so moving that up in that sense is absolutely critical. So those are the kind of things that we're building. And avert, as I mentioned, is critical. We're expanding access to Aristotle to treat and avert to countries outside of North America, UK, EU via partnerships. We've got considerable interest in that. We will bring those up in ways. And in fact, that may expand even into Aristotle as well. So it could be very, very interesting. We're adding additional cancers to Aristotle. I think as we've talked before, we're not looking to, in actual fact, try and do 50 cancers. We think that's an inappropriate strategy. We're going much more with a limited number of cancers, but notably those that have standard of care behind them. And what we want to do is we want to go deep with them. And so it's by deepening the offering, we want to be able to stage over time, select cancers, We're starting with colorectal. We're moving to breast and then lung so that we can be able to differentiate not only the stage of cancer, but obviously follow them over time. So that is what we've set for ourselves for 2022. And obviously together with this goes the incremental revenue that we expect to flow very clearly from this. Matt, hand over to you.